Fluidigm Announces New Co-Marketing Program under Collaboration Agreement with Visiopharm, Offering AI-Based Image Analysis Software
October 12 2021 - 08:30AM
Fluidigm Corporation (NASDAQ:FLDM), an innovative biotechnology
tools provider with a vision to improve life through comprehensive
health insight, today announced a new co-marketing program to offer
Visiopharm® image analysis software for faster and more streamlined
analysis of data acquired through Imaging Mass Cytometry™ (IMC™).
The program is the latest phase of an ongoing collaboration between
the two companies.
Visiopharm is a world leader in image analysis, with a mission
to transform pathology through AI-based image analysis and workflow
standardization, offering solutions for digital pathology.
New software developed in collaboration with Visiopharm will
enable native reading of data files from the Hyperion™ Imaging
System, which uses IMC technology, imported into Visiopharm
analysis tools. The new software will be launched at the 2021
Fluidigm IMC Summit on October 21.
“As part of this latest milestone in our collaboration with
Fluidigm, Visiopharm becomes the first company to provide
third-party software that enables native reading of Imaging Mass
Cytometry data files, with all metadata and imagery intact,
eliminating the need for conversion to an intermediate format,”
said Visiopharm CTO Johan Doré Hansen. “This simplifies the
workflow, enabling faster analysis of cellular phenotypes and their
interrelationships within the spatial context of the tissue
microenvironment.
“With advanced capabilities for high-plex analysis and
subsequent data mining, we believe Visiopharm is the partner of
choice for the analysis of Imaging Mass Cytometry data files, and
this enhancement will be yet another reason for researchers to
choose IMC as the premier tool for uncovering meaningful new
insights in health and disease.”
Globally, mass cytometry is utilized by 9 of the top 10 pharma
companies. Mass cytometry technologies, including CyTOF®, Imaging
Mass Cytometry and Maxpar® Direct™, have been used in more
than 160 National Clinical Trials.
“The translational and clinical research testing markets have
come to rely upon the Hyperion Imaging System for imaging solutions
for biomarker discovery and drug development,” said Chris
Linthwaite, President and CEO. “We are excited to partner with
Visiopharm to further expand the ecosystem of Imaging Mass
Cytometry data analysis tools, which provide valuable insights and
advance health care decision making.”
About FluidigmFluidigm (Nasdaq:FLDM)
focuses on the most pressing needs in translational and clinical
research, including cancer, immunology, and immunotherapy. Using
proprietary CyTOF and microfluidics technologies, we develop,
manufacture, and market multi-omic solutions to drive meaningful
insights in health and disease, identify biomarkers to inform
decisions, and accelerate the development of more effective
therapies. Our customers are leading academic, government,
pharmaceutical, biotechnology, plant and animal research, and
clinical laboratories worldwide. Together with them, we strive to
increase the quality of life for all. For more information,
visit fluidigm.com.
Fluidigm, the Fluidigm logo, CyTOF, Hyperion, Imaging
Mass Cytometry, IMC, and Maxpar are trademarks and/or registered
trademarks of Fluidigm Corporation or its affiliates
in the United States and/or other countries. All
other trademarks are the sole property of their respective owners.
Fluidigm products are provided for Research Use
Only. Not for use in diagnostic procedures.
Forward-Looking Statements for
Fluidigm This press release contains forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995, including, among others, statements regarding
the benefits of a collaboration and Fluidigm technologies and
demand for Fluidigm products and services. Forward-looking
statements are subject to numerous risks and uncertainties that
could cause actual results to differ materially from currently
anticipated results, including but not limited to risks relating to
the potential adverse effects of the coronavirus pandemic on our
business and operating results, potential product performance and
quality issues, intellectual property risks, competition,
uncertainties in contractual relationships, and reductions in
research and development spending or changes in budget priorities
by customers. Information on these and additional risks and
uncertainties and other information affecting Fluidigm business and
operating results is contained in Fluidigm’s Annual Report on Form
10-K for the year ended December 31, 2020, and in its other filings
with the Securities and Exchange Commission. These forward-looking
statements speak only as of the date hereof. Fluidigm disclaims any
obligation to update these forward-looking statements except as may
be required by law.
About VisiopharmVisiopharm is a world leader in
AI-based image analysis and workflow standardization solutions for
digital pathology. The pioneering image analysis tools support
thousands of scientists and pathologists in academic institutions
and the biopharmaceutical industry. In Europe, Visiopharm offers
several CE-IVD APPs as diagnostic decision support. With the most
advanced and sophisticated artificial intelligence and deep
learning, Visiopharm delivers accurate results and integrated
workflows for precision medicine. Visiopharm was founded in 2001
and is privately owned. The company operates internationally with
over 900 licenses and countless users in more than 40 countries.
The company headquarters are in Denmark’s Medicon Valley, with
offices in Sweden, England, Germany, and the United States.
Available InformationWe use our website
(fluidigm.com), investor site (investors.fluidigm.com), corporate
Twitter account (@fluidigm), Facebook page (facebook.com/Fluidigm),
and LinkedIn page (linkedin.com/company/fluidigm-corporation) as
channels of distribution of information about our products, our
planned financial and other announcements, our attendance at
upcoming investor and industry conferences, and other matters. Such
information may be deemed material information, and we may use
these channels to comply with our disclosure obligations under
Regulation FD. Therefore, investors should monitor our website and
our social media accounts in addition to following our press
releases, SEC filings, public conference calls, and
webcasts.
Fluidigm
Media:Mark SpearmanSenior Director, Corporate
Communications650 243 6621mark.spearman@fluidigm.com
Investors:Peter DeNardo415 389
6400ir@fluidigm.com
Fluidigm (NASDAQ:FLDM)
Historical Stock Chart
From Feb 2024 to Mar 2024
Fluidigm (NASDAQ:FLDM)
Historical Stock Chart
From Mar 2023 to Mar 2024